| Name | Title | Contact Details |
|---|
VentureMed Group, Inc. is a commercial-stage medical device company that develops and markets cost-effective interventional devices to improve the treatment of peripheral artery disease.
St Jude Medical is a Sylmar, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ProSomnus is the first manufacturer of precision, mass-customized Precision Oral Appliance Therapy devices to treat OSA, which affects over 74 million Americans and is associated with serious comorbidities, including heart failure, stroke, hypertension, morbid obesity and type 2 diabetes. ProSomnus`s patented devices are a more comfortable and less invasive alternative to Continuous Positive Airway Pressure (CPAP) therapy, and lead to more effective and patient-preferred outcomes. With more than 150,000 patients treated, ProSomnus`s devices are the most prescribed Precision Oral Appliance Therapy in the U.S.
Patrick Treacy, Antony Koblish and Adele Oliva saw a unique opportunity for one company to demonstrate leadership and set the agenda for innovation in surgical oncology. Founded in 2015, with best-in-class innovation partners, Onkos Surgical will deliver high quality implants and instruments that meet the unique needs of musculoskeletal tumor patients. From modular segmental systems to customized solutions and patient specific products, Onkos Surgical will partner with surgeons to provide new innovations to help address complex cases. Onkos Surgical has capabilities to increase the speed and delivery of innovation. Onkos Surgical is leveraging new technologies, such as 3D printing, to meet the unique needs of the cancer patient or surgeon. Onkos Surgical will develop products for both hard and soft-tissue applications while continuing to explore strategic partnerships to differentiate our product portfolio. With great customer responsiveness, manufacturing lead-times and quality, our vision is to be able to service and support the needs of the surgical oncologist.
LuxCath is the leader in using fluorescence and optics to directly view lesions during cardiac ablation procedures. The company`s breakthrough technology offers the potential for dramatic evolution in the way ablation procedures are performed by assessing tissue contact and enabling direct lesion progression monitoring. LuxCath`s patented solution aims to ensure the quality of catheter lesions at the moment they are made. LuxCath enables constant optical tissue contact assessment and provides valuable lesion formation and progression information during each ablation.